S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
NASDAQ:VRNA

Verona Pharma Stock Forecast, Price & News

$9.27
-0.02 (-0.22 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.86
Now: $9.27▼
$9.46
50-Day Range
$7.29
MA: $8.29▼
$9.33
52-Week Range
$2.01
Now: $9.27▼
$15.71
Volume90,242 shs
Average Volume161,944 shs
Market Capitalization$122.05 million
P/E RatioN/A
Dividend YieldN/A
Beta0.4
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Verona Pharma logo

Headlines

Revisiting Verona Pharmaceuticals
March 2, 2021 |  seekingalpha.com
Verona Pharma plc 2020 Q4 - Results - Earnings Call Presentation
February 26, 2021 |  seekingalpha.com
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
February 25, 2021 |  feeds.benzinga.com
Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study
February 2, 2021 |  msn.com
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
February 2, 2021 |  finance.yahoo.com
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
January 14, 2021 |  finance.yahoo.com
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
January 5, 2021 |  finance.yahoo.com
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
January 5, 2021 |  feeds.benzinga.com
Is VRNA A Good Stock To Buy Now?
December 11, 2020 |  finance.yahoo.com
25 Best U.S. Cities to Live With Asthma
November 25, 2020 |  finance.yahoo.com
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
November 23, 2020 |  finance.yahoo.com
Verona Pharma EPS beats by $0.15
October 30, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRNA
Previous Symbol
CUSIPN/A
CIK1657312
Webwww.veronapharma.com
Phone44-20-3283-4200
Employees33
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.04
Current Ratio2.99
Quick Ratio2.99

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.28 per share
Price / Book2.83

Profitability

EPS (Most Recent Fiscal Year)($3.10)
Net Income$-40,780,000.00
Net MarginsN/A
Return on Equity-115.93%
Return on Assets-73.68%

Miscellaneous

Outstanding Shares13,166,000
Market Cap$122.05 million
Next Earnings Date4/29/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.69 out of 5 stars

Medical Sector

232nd out of 1,968 stocks

Pharmaceutical Preparations Industry

112th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$9.27
-0.02 (-0.22 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Verona Pharma (NASDAQ:VRNA) Frequently Asked Questions

Is Verona Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Verona Pharma stock.
View analyst ratings for Verona Pharma or view top-rated stocks.

What stocks does MarketBeat like better than Verona Pharma?

Wall Street analysts have given Verona Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verona Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Verona Pharma?

Verona Pharma saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 26,200 shares, a decrease of 61.6% from the January 28th total of 68,300 shares. Based on an average daily volume of 110,100 shares, the days-to-cover ratio is presently 0.2 days.
View Verona Pharma's Short Interest.

When is Verona Pharma's next earnings date?

Verona Pharma is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Verona Pharma.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) announced its earnings results on Thursday, February, 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.19.
View Verona Pharma's earnings history.

How has Verona Pharma's stock been impacted by Coronavirus (COVID-19)?

Verona Pharma's stock was trading at $4.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VRNA stock has increased by 91.5% and is now trading at $9.27.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for VRNA?

3 analysts have issued 12-month price objectives for Verona Pharma's stock. Their forecasts range from $17.00 to $23.00. On average, they anticipate Verona Pharma's share price to reach $19.00 in the next year. This suggests a possible upside of 105.0% from the stock's current price.
View analysts' price targets for Verona Pharma or view top-rated stocks among Wall Street analysts.

Who are Verona Pharma's key executives?

Verona Pharma's management team includes the following people:
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 54)
  • Dr. Kathleen A. Rickard, Chief Medical Officer (Age 63)
  • Dr. David S. Zaccardelli, Pres, CEO & Director (Age 56)
  • Mr. Mark W. Hahn, Chief Financial Officer (Age 58)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 59)
  • Ms. Nina Church, Exec. Director of Global Clinical Devel.
  • Ben Harber, Company Sec.

Who are some of Verona Pharma's key competitors?

Some companies that are related to Verona Pharma include Wave Life Sciences (WVE), Akebia Therapeutics (AKBA), Aldeyra Therapeutics (ALDX), Evolus (EOLS), Mirum Pharmaceuticals (MIRM), Avadel Pharmaceuticals (AVDL), Inozyme Pharma (INZY), RAPT Therapeutics (RAPT), Selecta Biosciences (SELB), DURECT (DRRX), TherapeuticsMD (TXMD), MEI Pharma (MEIP), Athersys (ATHX), Orphazyme A/S (ORPH) and UroGen Pharma (URGN).
View all of VRNA's competitors.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Ghost Tree Capital LLC (6.15%), D.A. Davidson & CO. (0.75%), HighVista Strategies LLC (0.20%), Renaissance Technologies LLC (0.19%), IHT Wealth Management LLC (0.14%) and Hsbc Holdings PLC (0.11%).
View institutional ownership trends for Verona Pharma.

Which major investors are selling Verona Pharma stock?

VRNA stock was sold by a variety of institutional investors in the last quarter, including IHT Wealth Management LLC.
View insider buying and selling activity for Verona Pharma or view top insider-selling stocks.

Which major investors are buying Verona Pharma stock?

VRNA stock was purchased by a variety of institutional investors in the last quarter, including HighVista Strategies LLC, Renaissance Technologies LLC, Hsbc Holdings PLC, D.A. Davidson & CO., and Ghost Tree Capital LLC.
View insider buying and selling activity for Verona Pharma or or view top insider-buying stocks.

How do I buy shares of Verona Pharma?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $9.27.

How much money does Verona Pharma make?

Verona Pharma has a market capitalization of $122.05 million. The company earns $-40,780,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

How many employees does Verona Pharma have?

Verona Pharma employs 33 workers across the globe.

What is Verona Pharma's official website?

The official website for Verona Pharma is www.veronapharma.com.

Where are Verona Pharma's headquarters?

Verona Pharma is headquartered at 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.